Resting heart rate: an independent predictor of congestive heart failure.

data for the overall angina burden and its impact on patients’ quality of life. These analyses of the effect of ranolazine on quality of life measures have been completed, and recently published (2). The third question is whether we observed a glucoseand HBA1c-lowering effect of ranolazine in TERISA. The objective of TERISA was to prospectively assess the antianginal effectiveness of ranolazine in patients with T2DM, not its potential glucose-lowering effect. Therefore, although HBA1c values were collected at baseline for cohort characterization, no repeat measurements of HBA1c were obtained following randomization, and no inference with regard to ranolazine-mediated lowering of HBA1c can be made from this clinical trial. Notably, an extensive phase 3 drug development program to assess the potential glycometabolic effects of ranolazine in a rigorously controlled fashion is currently ongoing.